Similar Patency with Significantly Less Drug

View 12-month results of COMPARE-1, the world’s first randomized head-to-head trial comparing the low dose Ranger DCB to the higher dose IN.PACT DCB. View a perspectives video and download the data sheet.

Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies.

Boston Scientific Drug Eluting Clinical Program

Discover and download Boston Scientifics Drug Eluting Clinical Programm now.

Favorable twelve-month data for RANGER

Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.

RANGER DCB: Clinically proven in both randomized and real-world clinical trials!

The RANGER™ SFA trial exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.


MAJESTIC clinical study : Unprecedented Results at 2 years!

The Eluvia Drug-Eluting Stent System demonstrated an unprecedented 92.5% Freedom from TLR at 2 years.
About Drug-Eluting Technologies
Clinical Program
Resources Center
News & Events

WANT TO KNOW MORE?

Join our Drug-Eluting Technologies Community

Sign Up for Product Updates

Receive the latest news of Drug Eluting Technologies

SIGN UP